These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24668021)

  • 1. Ipragliflozin: first global approval.
    Poole RM; Dungo RT
    Drugs; 2014 Apr; 74(5):611-7. PubMed ID: 24668021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofogliflozin: first global approval.
    Poole RM; Prossler JE
    Drugs; 2014 Jun; 74(8):939-44. PubMed ID: 24848755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
    Kadokura T; Zhang W; Krauwinkel W; Leeflang S; Keirns J; Taniuchi Y; Nakajo I; Smulders R
    Clin Pharmacokinet; 2014 Nov; 53(11):975-88. PubMed ID: 25316572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
    Wang H; Yao G; Chen X; Ouyang J; Yang J
    Diabetes Res Clin Pract; 2019 Nov; 157():107867. PubMed ID: 31568801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luseogliflozin: first global approval.
    Markham A; Elkinson S
    Drugs; 2014 Jun; 74(8):945-50. PubMed ID: 24848756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
    Tahara A; Takasu T
    Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
    Shestakova MV; Wilding JPH; Wilpshaar W; Tretter R; Orlova VL; Verbovoy AF
    Diabetes Res Clin Pract; 2018 Dec; 146():240-250. PubMed ID: 30391333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
    Kashiwagi A; Yoshida S; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Satomi H; Kosakai Y; Kawamuki K
    J Diabetes Investig; 2016 Jul; 7(4):544-54. PubMed ID: 27181576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
    Hedrington MS; Davis SN
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):613-23. PubMed ID: 25643044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
    Takasu T; Hayashizaki Y; Tahara A; Kurosaki E; Takakura S
    Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):87-93. PubMed ID: 25311502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
    Tahara A; Takasu T
    Physiol Rep; 2019 Nov; 7(22):e14286. PubMed ID: 31782258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
    Tanaka A; Murohara T; Taguchi I; Eguchi K; Suzuki M; Kitakaze M; Sato Y; Ishizu T; Higashi Y; Yamada H; Nanasato M; Shimabukuro M; Teragawa H; Ueda S; Kodera S; Matsuhisa M; Kadokami T; Kario K; Nishio Y; Inoue T; Maemura K; Oyama J; Ohishi M; Sata M; Tomiyama H; Node K;
    Cardiovasc Diabetol; 2016 Sep; 15(1):133. PubMed ID: 27619983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.
    Fonseca VA; Ferrannini E; Wilding JP; Wilpshaar W; Dhanjal P; Ball G; Klasen S
    J Diabetes Complications; 2013; 27(3):268-73. PubMed ID: 23276620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    J Pharmacol Sci; 2012; 120(1):36-44. PubMed ID: 22971845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin: a new hope in the antidiabetic armamentarium.
    Katsi VK; Michalakeas CA; Grassos CE; Vamvakou GD; Lekakis JP; Tousoulis D; Stefanadis CI; Makris TK; Kallikazaros IE
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):216-20. PubMed ID: 24359233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canagliflozin: first global approval.
    Elkinson S; Scott LJ
    Drugs; 2013 Jun; 73(9):979-88. PubMed ID: 23729000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.